Children's Oncology Group

Hyundai Hope On Wheels Reaches a Lifetime Giving Milestone of a Quarter-Billion Dollars in 2024

Retrieved on: 
수요일, 3월 27, 2024
Research, Health, Cole, Survival rate, Disease, Hyundai Motor America, Patient, Hospital, Children's Oncology Group, Cancer, Hope, Life, Organic, COG, Hyundai, Multimedia, Courage, National Youth, Estate (law)

With this commitment, the organization reaches a lifetime giving milestone of a quarter-billion dollars as part of its 26th anniversary.

Key Points: 
  • With this commitment, the organization reaches a lifetime giving milestone of a quarter-billion dollars as part of its 26th anniversary.
  • "We are proud to have reached this incredible milestone for Hyundai Hope On Wheels, as it truly speaks to the commitment of Hyundai Motor America and its dealers to the cause of ending childhood cancer," said Kevin Reilly, vice chairman of the Hyundai Hope On Wheels Board of Directors, and president of Alexandria Hyundai.
  • Later this year, Hyundai Hope On Wheels will visit children's hospitals across the nation to present Hope On Wheels grant awards.
  • Primary funding for Hyundai Hope On Wheels comes from Hyundai Motor America and its more than 830 U.S. dealers.

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life

Retrieved on: 
월요일, 12월 11, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Well, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, KKI, Neoplasm, Blood, ECOG, Cancer, ANOVA, Erythroderma, Female, Quality of life, Children's Oncology Group, Nursing, Medical imaging

Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical,” said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • In multivariate analysis, worse HRQL was associated with being younger, female, moderate or severe pruritus and impaired function (as measured by ECOG PS).

New Post Hoc Analysis from MAVORIC Trial Sheds Light on Burden of Cutaneous T-cell Lymphoma on Health-related Quality of Life

Retrieved on: 
월요일, 12월 11, 2023
Well, American Society of Hematology, Mycosis fungoides, Organ, Neuropsychological test, CTCL, Cutaneous T-cell lymphoma, Central Statistics Office (India), Disease, Skin, Eastern Cooperative Oncology Group, Modified, Patient, Itch, Bivariate, Lymph, Neoplasm, TSE, Blood, ECOG, Cancer, ANOVA, Erythroderma, Society, Female, Quality of life, Children's Oncology Group, Kyowa Kirin, B-cell lymphoma

PRINCETON, N.J., Dec. 11, 2023 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced health-related quality of life (HRQL) findings from a post hoc analysis of the MAVORIC trial in patients with mycosis fungoides (MF) or Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL). Researchers analyzed baseline data collected prior to initiation of study treatments and found the symptoms of advanced MF/SS affected HRQL across all domains, with poorer HRQL associated with being younger in age, female, having moderate or severe itching, and impaired function as measured by the Eastern Cooperative Oncology Group performance status (ECOG PS).

Key Points: 
  • Understanding how symptoms impact an individual physically, emotionally as well as in their daily life is critical," said Susan Thornton, Chief Executive Officer, Cutaneous Lymphoma Foundation and one of the study authors.
  • Bivariate analysis (t-tests and ANOVA) was used to identify demographic and medical history variables that had a relationship with HRQL.
  • LASSO (least absolute shrinkage and selection operator) regression analysis was used to identify factors that may drive poor HRQL.
  • Researchers concluded that assessing a patient's disease concerns may help guide treatment goals and therapeutic choice.

HYUNDAI HOPE ON WHEELS ANNOUNCES 2023 GRANT AWARD WINNERS

Retrieved on: 
수요일, 9월 6, 2023
Social responsibility, Paint, Hyundai Motor America, Survival, Cancer, National Institutes of Health, Hope, COG, Research, Children's Oncology Group, Backward Regions Grant Fund, Estate (law), Hospital, Bridge, Child, Oncology, Dietary supplement, Birth control, Hyundai, Wheel

FOUNTAIN VALLEY, Calif., Sept. 6, 2023 /PRNewswire/ -- Hyundai Hope On Wheels, a 501(c)(3) nonprofit organization supported by Hyundai Motor America and its 830 U.S. dealers, announced the 2023 winners of its annual research and programmatic grants, part of Hyundai Hope on Wheels' $25 million commitment in 2023 to fund pediatric cancer research grants and survivorship efforts.

Key Points: 
  • FOUNTAIN VALLEY, Calif., Sept. 6, 2023 /PRNewswire/ -- Hyundai Hope On Wheels, a 501(c)(3) nonprofit organization supported by Hyundai Motor America and its 830 U.S. dealers, announced the 2023 winners of its annual research and programmatic grants, part of Hyundai Hope on Wheels' $25 million commitment in 2023 to fund pediatric cancer research grants and survivorship efforts.
  • "Over the past 25 years, Hyundai Hope On Wheels has been creating hope for families facing childhood cancer by investing in life-saving research, treatment, and support," said John Guastaferro, executive director, Hyundai Hope On Wheels.
  • Hyundai Hope On Wheels was inspired by a group of New England Hyundai dealers in 1998, with the goal to end childhood cancer.
  • The Hyundai Scholar Hope Grant is a 2-year award competitively selected for translational research, and the Hyundai Young Investigator Grant is a 2-year award competitively selected for innovative research.

Lymphoma Research Foundation to Honor Esteemed Lymphoma Physician Kara Kelly, MD at Annual Gala on September 28

Retrieved on: 
수요일, 8월 2, 2023
Lymphoma, SAB, University, Pediatrics, Therapy, Senior, Jacobs School of Medicine and Biomedical Sciences, Bone marrow, American Biographical Institute, John R. Oishei Children's Hospital, Children's Oncology Group, Cancer, Buffalo buffalo Buffalo buffalo buffalo buffalo Buffalo buffalo, Buffalo, Research, Roswell Park, Biomedical sciences, Young adult, Hodgkin, Waldemar, LRF, MD, Patient, Division, American Society of Pediatric Hematology/Oncology, Hospital, Leukemia, Health, Ziegfeld Theatre (1969), Pharmaceutical industry, Nursing, Genmab

NEW YORK, Aug. 2, 2023 /PRNewswire-PRWeb/ -- The Lymphoma Research Foundation (LRF), the nation's largest non-profit organization dedicated exclusively to funding innovative lymphoma research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives, and patient services, will host its 2023 Annual Gala on Thursday, September 28, at the Ziegfeld Ballroom in New York City.

Key Points: 
  • Genmab will be presented with the Lymphoma Research Foundation's Corporate Leadership Award for excellence in development of differentiated antibody therapeutics.
  • Honored at this year's gala will be LRF Scientific Advisory Board (SAB) member Kara Kelly, MD, who will recieve LRF's Distinguished Leadership Award.
  • "I am so incredibly honored to be receiving the Distinguished Leadership Award from the Lymphoma Research Foundation.'
  • We are proud to support the important work of the Lymphoma Research Foundation in achieving our shared goals for patients."

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

Retrieved on: 
금요일, 4월 14, 2023
Lijun International Pharmaceutical (Holding) Co. Ltd., PK, Carcinoma, AACR, PD, Neutrophil, Genetics, Half-life, Progression-free survival, Chills, Pharmacokinetics, American Association for Cancer Research, Itch, Children's Oncology Group, Doctor of Philosophy, Hypothyroidism, PFS, Renal cell carcinoma, Eastern Cooperative Oncology Group, Sarcoma, Primary peritoneal carcinoma, MD, Patient, ECOG, Cancer, AM, MSI-H, Toxicity, Therapy, ORR, Safety, Fatigue, Pharmaceutical industry, Vaccine, CD200R1

23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target.

Key Points: 
  • 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics (PK) and peripheral saturation of the CD200R1 target.
  • Based on the Phase 1 data, a dose of 23ME-00610 given at 1400 mg intravenously every 3 weeks was selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a (Phase 2a) 23ME-00610 study.
  • Among study participants, most experienced at least 1 treatment related adverse event (TRAE); the majority were Grade 1 or 2.
  • A RP2D of 1400 mg 23ME-00610 was selected for evaluation in the Phase 2a portion of the study.

HYUNDAI HOPE ON WHEELS CELEBRATES 25 YEARS WITH A $25 MILLION DONATION TO PEDIATRIC CANCER RESEARCH

Retrieved on: 
수요일, 4월 5, 2023
Social responsibility, Survivor, Perseverance, HOPE, Hyundai Motor America, Cancer, National Institutes of Health, Hope, COG, National Youth, Research, Multimedia, Children's Oncology Group, History, Social media, Hospital, Hyundai, Patient, National Childhood Cancer Awareness Month, Growth, Courage, Automotive industry, Birth control, Dietary supplement

In honor of this milestone, Hyundai Hope On Wheels today announced plans to award $25 million in research grants this year, its largest donation in a single year, bringing its total giving to $225 million since its inception.

Key Points: 
  • In honor of this milestone, Hyundai Hope On Wheels today announced plans to award $25 million in research grants this year, its largest donation in a single year, bringing its total giving to $225 million since its inception.
  • "Hyundai Hope On Wheels is honored to have reached this milestone, which humbly started as a local initiative in New England 25 years ago," said Kevin Reilly, vice chairman of the Hyundai Hope On Wheels Board of Directors, and president of Alexandria Hyundai.
  • Hyundai Hope On Wheels is one of the largest nonprofit funders of pediatric cancer research in the country.
  • In 2023, Hyundai Hope On Wheels will surpass a lifetime total donation of $225 million in support of more than 1,300 childhood cancer research grants.

Researchers Show Lorlatinib is Safe and Effective for Patients with ALK-Driven Relapsed/Refractory High-Risk Neuroblastoma

Retrieved on: 
월요일, 4월 3, 2023
Army, Neoplasm, Band of Parents, Science, Discovery, MD, Patient, Disease, Children's Hospital of Philadelphia, ALK, Neuroblastoma, Emory University, St. Baldrick's Foundation, Alex's Lemonade Stand Foundation, Pediatrics, Consortium, CHOP, Wipe Out Kids' Cancer, Crizotinib, Research, Lung cancer, Pfizer, MYCN, Anaplastic lymphoma kinase, DOI, Hospital, FDA, NCI, Alvin J. Siteman Cancer Center, Safety, New Approach to Appraisal, Emory University School of Medicine, Winship Cancer Institute, Lipid, Development of the human body, COG, Children's Oncology Group, Weight gain, National Cancer Institute, International Society, Cancer, Adolescence, Band, Ronan (song), Clinical trial, Abdomen, Pharmaceutical industry, Medical imaging, Child, Nature Medicine, Parent

PHILADELPHIA, April 3, 2023 /PRNewswire/ -- In a significant step for the treatment of neuroblastoma, an international group of researchers led by Children's Hospital of Philadelphia (CHOP), Winship Cancer Institute of Emory University and the New Approaches to Neuroblastoma Therapy (NANT) Consortium has shown that the targeted therapy lorlatinib is safe and effective in treating high-risk neuroblastoma. The findings, published today in Nature Medicine, have led to a major amendment in a phase 3 Children's Oncology Group (COG) clinical trial, which has incorporated lorlatinib for newly diagnosed ALK-driven high-risk neuroblastoma, as well as a planned amendment to the European phase 3 trial in collaboration with the International Society of Paediatric Oncology European Neuroblastoma (SIOPEN).

Key Points: 
  • The difficulties we experienced in targeting ALK with crizotinib in neuroblastoma motivated us to find a more potent ALK inhibitor.
  • In the phase 1 NANT trial, researchers found that lorlatinib given alone or in combination with chemotherapy was safe and tolerable in pediatric, adolescent, and adult patients with relapsed/refractory ALK-driven neuroblastoma.
  • The researchers noted that younger patients treated with lorlatinib alone – particularly those with amplification of an oncogene called MYCN – had fewer responses compared to older patients.
  • "Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase I trial results," Nature Medicine, April 3, 2023, DOI: 10.1038/s41591-023-02297-5

DCG Giving, a Dave Cantin Group Partnership, Delivers a Knockout Punch to Pediatric Cancer Through its Fundraising Auction of Mike Tyson Autographed Boxing Gloves

Retrieved on: 
목요일, 2월 23, 2023
Other Health, Other Philanthropy, Automotive, Oncology, Finance, Consulting, Fund Raising, Foundation, Professional Services, Boxing, Philanthropy, Entertainment, General Health, Sports, Health, Other Automotive, General Automotive, Celebrity, Del, DCG, Pediatrics, Protein, Survival, Metabolism, Sarcoma, Disease, Brain, National Automobile Dealers Association, Partnership, Hematology, Research, NADA, Child, Division, NIH, Adolescence, University of Texas Southwestern Medical Center, Children's Oncology Group, Multimedia, VIP, COG, Community, Dave Cantin, Vaccine, Hospital, Cancer

The event auctioned off autographed boxing gloves by Mike Tyson.

Key Points: 
  • The event auctioned off autographed boxing gloves by Mike Tyson.
  • View the full release here: https://www.businesswire.com/news/home/20230223005951/en/
    Mike Tyson (left), Dave Cantin, Executive Chairman and CEO (center), and Valentina Nejfelt celebrate the auctioning of autographed boxing gloves at Dave Cantin Group’s event on behalf of DCG Giving.
  • “Only about 4% of all federal funding for cancer research is spent on projects involving children's cancers-that is simply not enough,” says Dave Cantin, Executive Chairman and CEO, DCG.
  • The Division is nationally distinguished for its design and conduct of NIH-funded multicenter clinical trials involving childhood cancer and blood disease.

DCG Acquisitions, a Dave Cantin Group Company, Closed More Than $1 Billion in Total Acquisition Value in 2022 for Second Consecutive Year

Retrieved on: 
화요일, 1월 24, 2023
General Automotive, Professional Services, Automotive, Finance, Children's Oncology Group, Hospital, Cantin, UT, Acquisition, Northwestern University Dance Marathon, Anne, COG, Kia, DCG, Child, Hyundai, Adolescence, UPMC, Retail, Cryptocurrency

The Dave Cantin Group (DCG), one of the largest automotive industry financial advisory services companies specializing in buy/sell transactions, announced that DCG Acquisitions , one of the leading mergers and acquisitions firms, closed more than $1 billion in total acquisition value for the second consecutive year.

Key Points: 
  • The Dave Cantin Group (DCG), one of the largest automotive industry financial advisory services companies specializing in buy/sell transactions, announced that DCG Acquisitions , one of the leading mergers and acquisitions firms, closed more than $1 billion in total acquisition value for the second consecutive year.
  • “The number and more importantly, the valuation of dealership acquisitions in 2022 exceeded our expectations,” said Dave Cantin, Executive Chairman and CEO of DCG.
  • Most notable acquisitions include:
    Most notably, DCG Acquisitions completed 60 dealership franchise transactions in 2022, an increase of 50% over 2021, and 33% of its total 2022 transactions were multi-rooftops.
  • Funds raised from a percentage of every transaction DCG Acquisitions closed supported local resources where the transactions took place.